新型冠状病毒肺炎（预）临床疫苗研发现状。
Current Status of COVID-19 (Pre)Clinical Vaccine Development.
机构信息
Department of Pharmaceutics, Ghent University, Belgium.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
出版信息
Angew Chem Int Ed Engl. 2020 Oct 19;59(43):18885-18897. doi: 10.1002/anie.202008319. Epub 2020 Sep 2.
Abstract
The current COVID-19 pandemic has a tremendous impact on daily life world-wide. Despite the ability to dampen the spread of SARS-CoV-2, the causative agent of the diseases, through restrictive interventions, it is believed that only effective vaccines will provide sufficient control over the disease and revert societal live back to normal. At present, a double-digit number of efforts are devoted to the development of a vaccine against COVID-19. Here, we provide an overview of these (pre)clinical efforts and provide background information on the technologies behind these vaccines. In addition, we discuss potential hurdles that need to be addressed prior to mass scale clinical translation of successful vaccine candidates.
摘要
当前的 COVID-19 大流行对全球的日常生活产生了巨大影响。尽管通过限制干预措施能够抑制 SARS-CoV-2（引发该疾病的病原体）的传播，但人们认为只有有效的疫苗才能对该疾病进行充分控制，并使社会生活恢复正常。目前，有十多个团队致力于开发 COVID-19 疫苗。在这里，我们概述了这些（临床前）努力，并提供了这些疫苗背后技术的背景信息。此外，我们还讨论了在成功的候选疫苗大规模临床转化之前需要解决的潜在障碍。
相似文献
1
Current Status of COVID-19 (Pre)Clinical Vaccine Development.
Angew Chem Int Ed Engl. 2020 Oct 19;59(43):18885-18897. doi: 10.1002/anie.202008319. Epub 2020 Sep 2.
2
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Int Immunopharmacol. 2021 Jul;96:107763. doi: 10.1016/j.intimp.2021.107763. Epub 2021 May 6.
3
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection 2020.
4
On the road to ending the COVID-19 pandemic: Are we there yet?
Virology. 2021 May;557:70-85. doi: 10.1016/j.virol.2021.02.003. Epub 2021 Feb 26.
5
COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies.
Hum Vaccin Immunother. 2021 Apr 3;17(4):1122-1127. doi: 10.1080/21645515.2020.1822136. Epub 2020 Sep 29.
6
COVID-19 vaccines.
Curr Opin Immunol. 2021 Aug;71:111-116. doi: 10.1016/j.coi.2021.07.003. Epub 2021 Jul 12.
7
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
8
COVID-19 Vaccine: A comprehensive status report.
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
9
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Vaccine. 2021 Jan 8;39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24.
10
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.
J Korean Med Sci. 2021 Feb 8;36(6):e54. doi: 10.3346/jkms.2021.36.e54.
引用本文的文献
1
Incidence and management of the main serious adverse events reported after COVID-19 vaccination.
Pharmacol Res Perspect. 2024 Jun;12(3):e1224. doi: 10.1002/prp2.1224.
2
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.
Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058.
3
Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine.
Sci Rep. 2023 Nov 13;13(1):19736. doi: 10.1038/s41598-023-45735-7.
4
Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity.
Small. 2024 Mar;20(10):e2306892. doi: 10.1002/smll.202306892. Epub 2023 Oct 22.
5
A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.
Vaccines (Basel). 2023 May 31;11(6):1045. doi: 10.3390/vaccines11061045.
6
Viral vector and nucleic acid vaccines against COVID-19: A narrative review.
Front Microbiol. 2022 Aug 31;13:984536. doi: 10.3389/fmicb.2022.984536. eCollection 2022.
7
Mucus-Inspired Dynamic Hydrogels: Synthesis and Future Perspectives.
J Am Chem Soc. 2022 Nov 9;144(44):20137-20152. doi: 10.1021/jacs.1c13547. Epub 2022 Sep 8.
8
Current clinical status of new COVID-19 vaccines and immunotherapy.
Environ Sci Pollut Res Int. 2022 Oct;29(47):70772-70807. doi: 10.1007/s11356-022-22661-1. Epub 2022 Sep 5.
9
Innovations and Challenges in Electroanalytical Tools for Rapid Biosurveillance of SARS-CoV-2.
Adv Mater Technol. 2022 Jun 23:2200208. doi: 10.1002/admt.202200208.
10
Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19.
Front Immunol. 2022 Jul 4;13:879792. doi: 10.3389/fimmu.2022.879792. eCollection 2022.
本文引用的文献
1
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
2
Immunogenicity of a DNA vaccine candidate for COVID-19.
Nat Commun. 2020 May 20;11(1):2601. doi: 10.1038/s41467-020-16505-0.
3
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Lancet Infect Dis. 2020 Jul;20(7):816-826. doi: 10.1016/S1473-3099(20)30160-2. Epub 2020 Apr 21.
4
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
5
News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine.
Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8218-8221. doi: 10.1073/pnas.2005456117. Epub 2020 Mar 30.
6
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Nature. 2020 May;581(7807):215-220. doi: 10.1038/s41586-020-2180-5. Epub 2020 Mar 30.
7
Genetic diversity and evolution of SARS-CoV-2.
Infect Genet Evol. 2020 Jul;81:104260. doi: 10.1016/j.meegid.2020.104260. Epub 2020 Feb 21.
8
A new coronavirus associated with human respiratory disease in China.
Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
9
Opportunities and Challenges in the Delivery of mRNA-based Vaccines.
Pharmaceutics. 2020 Jan 28;12(2):102. doi: 10.3390/pharmaceutics12020102.
10
Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.
Lancet Infect Dis. 2020 Apr;20(4):435-444. doi: 10.1016/S1473-3099(19)30584-5. Epub 2020 Jan 21.
Zotero 插件